Big Pharma has feels for mifepristone Corporations are not people, my friends. They have no feelings, only appetites and strong instincts for self-preservation. In that way, they are primitively animal-ish the way A.I. simulates thought. But damned if they aren’t territorial, too. David Dayen considers Big Pharma’s reaction to the potential banning of mifepristone: The pharmaceutical industry is very upset. Right-wing federal judge Matthew Kacsmaryk’s ruling overturning the Food and Drug Administration’s 23-year-old approval of abortion medication mifepristone could severely damage companies’ ability to develop and market prescription drugs. Companies could spend a fortune getting a drug approved, only to see the courts take issue with the process, and the money washed down the drain. To them, it’s the worst thing a court ruling can be: bad for business. That’s why Big Pharma is speaking out. On Monday, industry leaders fashioned an open letter condemning Kacsmaryk’s “act of judicial interference,” which “creates uncertainty for the entire biopharma industry … Adding regulatory uncertainty to the already inherently risky work of discovering and developing new medicines will likely have the effect of reducing incentives for investment, endangering the innovation that characterizes our industry.” Over 400 industry CEOs and top executives have signed on to the letter, as of Tuesday afternoon. Not that Big Pharma cares about its customers. The group displays not even a ChatGPT level of feelings for them. The words woman or women appear nowhere in their 400-word missive. But the group does experience a primitive sense of betrayal, Dayen observes: [T]he industry’s lament…